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Background: In rare condition, combined thymic epithelial tumors showing either type A or type B thymomas areas
combined with thymic carcinoma components may occur in thymus. Mucoepidermoid carcinoma (MEC) of the
thymus is rare in thymic carcinoma, and so far there is no report to describe a combined epithelial tumor of thymus
with MEC component. We report an unusual case of combined thymic MEC/type B2 thymoma in a middle-aged male
occurring in a mass of anterior mediastinum. Case report: A 51-year-old Chinese male patient presented with a
6-month history of right ptosis and progressive muscle weakness. Computed tomography (CT) examination revealed a
solitary, well-circumscribed mass was in the anterior mediastinum with mild heterogeneous enhancement.
Histologically, the mass contained two separated components and displayed typically histological features of low-grade
MEC and type B2 thymoma, respectively. There was no gradual transition of these two components observed in mass,
and no enlarged lymph node was found in the surrounding tissues. A diagnosis of combined thymic MEC/type B2
thymoma was made. The patient received thymectomy to resect the mass totally. After surgery, chemotherapy with
regiments of cisplatin and mitomycin, and radiotherapy of the main tumor bed were performed on the patient. There
was no evidence of tumor recurrence during the period of 12 months follow-up.
Conclusion: To our best knowledge, this is the first report of combined thymic epithelial tumor with MEC component.
Although this tumor is rare, the diagnosis of a thymic MEC should be taken into consideration when a combined
epithelial tumor is occasionally encountered in thymus.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
9721397571157894
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Differential diagnosisBackground
Primary thymic carcinoma is a rare tumor of the anter-
ior mediastinum. Mucoepidermoid carcinoma (MEC) of
the thymus is rare in thymic caircinoma, and comprises
approximately 2% of published thymic carcinoma [1,2].
Up to date, no more than 30 cases of thymic MEC have
been described in the literature [3-15]. In rare condition,
combined thymic epithelial tumors showing either type
A or type B thymomas areas combined with thymic car-
cinoma components may occur primarily in thymus, and* Correspondence: lizhi@mail.sysu.edu.cn
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stated.are exceptionally rare (<1%) [16]. Among the combined
thymic epithelial tumors, over 80% of tumors have typ-
ical B2 and B3 differentiation. The carcinoma compo-
nent in the most case is a squamous cell carcinoma.
Lymphoepithelioma-like, sarcomatoid/anaplastic or un-
differentiated carcinomas are uncommon. However, to
our knowledge, so far there is no report to describe a
coexistence of thymoma and primary MEC within the
same mediastinal tumor in English literatures. Herein
we report a middle-aged male patient with MEC com-
bined with type B2 thymoma in the same nodule of an-
terior mediastinum. Histopathological findings and
imaging features, as well as outcome and differential
diagnosis are to be discussed.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Patient and clinical management
A 51-year-old Chinese male presented with a 6-month
history of right ptosis and progressive muscle weakness.
The patient had been diagnosed as myasthenia gravis at
local hospital 6 months before, but for unknown reasons,
he failed to receive workup and management at that time.
Before one day the patient was admitted to our hospital,
he suffered with a sudden onset of dysarthria. Therefore,
the patient referred to our hospital for further examination
and treatment. Physical examination showed right-sided
partial ptosis. Diplopia was noticed on right lateral gaze
due to right lateral rectus weakness. The patient did not
have dysphagia or dyspnoea. But he was having generalized
weakness in all his extremities, both proximal and distal,
with marked diurnal variation in the form of more weak-
ness during the evening. A confirmatory electrophysio-
logical study with repetitive nerve stimulation showed
decrement in amplitude of action potentials with further
reduction post exercise and recovery after 15 minutes.
Acetylcholine receptor (AChR) binding antibodies were
markedly elevated. However, other routine laboratory test,
including blood count, differential, liver and renal function,
were within the normal range. A chest computed tomog-
raphy (CT) scan demonstrated a solid mass, measuring
5.4 × 3.7 × 2.6 cm, with focal heterogeneously enhance-
ment, in the right anterior mediastinum. The tumor was
observed to adhere to the wall of aorta but did not infil-
trate it. Minimal amount of right pleural effusion and peri-
cardial effusion were associated, but neither enlarged
lymph node nor remarkable image finding was noted in
the lung parenchyma (Figure 1). A CT guided fine needle
biopsy of the anterior mediastinal mass was performed and
pathological examination showed predominantly epithelial
neoplastic cells with pan-cytokeratin (AE1/AE3) positive in
a lymphoid component background suggesting a thymoma.
Therefore, a preoperative diagnosis was thymoma and the
tumor was totally resected. At surgery, the main tumor lo-
cated in the right lobe of the thymus was found to haveFigure 1 Preoperative chest radiology of lesion. (a) Chest CT image sh
The tumor was observed to adhere to the wall of great vessel. (b) The con
heterogeneous enhancement adhered, but not invaded the wall of great vadhered to the periaortic tissues, but no invasion of the
wall of aorta was observed. Thymectomy and resection of
the adherent tissues were performed.
Hisopathological findings
Macroscopical examination revealed a gray-red solitary
nodular mass, and measured 5.0 × 3.5 × 2.0 cm. The mass
was well-circumscribed, but there was no fibrous capsule
around the mass and no cystic cavity observed in the mass
(Figure 2). Under the microscopical examination, part of
nodular mass was composed of solid and invasive nests of
well-differentiated epidermoid cells with desmoplastic
stroma. The mucin-producing and intermediate cells were
also observed in the tumor. These tumor cells were inter-
mingled or intimately mixed with epidermoid cells. Mucin-
producing cells were cuboidal, columnar, or goblet-like
with bland nuclear morphology. Bands of fibrous connect-
ive tissue were observed among the neoplastic elements.
There was no extensive necrosis and neural invasion. Mi-
totic figures were infrequent and there was no remarkable
cellular pleomorphism. Immunohistochemically, the epi-
dermoid cells of the tumor were positive to pan-CK (AE1/
AE3), CK5/6, CK7 and p63, but negative to CD5. Mucin-
producing cells were negative to CK5/6 and p63. Alcian
blue staining revealed mucin in the cytoplasm of the
mucin-producing cells (Figure 3). This part of tumor was
diagnosed as low-grade MEC according to the histopatho-
logical criteria of WHO classification [17]. Interestingly,
however, type B2 thymoma could be observed in other area
of the same nodular mass. In this area, neoplastic cells
were large and polygonal with large nuclei and prominent
central nucleoli. The neoplastic cells formed delicate lose
network, and small epidermoid foci resembling abortive
Hassall’s corpuscles could be observed among the neoplas-
tic epithelial cells, but no mucin-producing cells were
found in these epidermoid foci. In these areas, the neo-
plastic cells were outnumbered by non-neoplastic lympho-
cytes. By immunohistochemical staining, the neoplastic
cells revealed the positivity for pan-CK (AE1/AE3), CK5/6,owed a well-defined mass in right anterior mediastinum (white arrow).
trast enhanced CT scan showed the solid mass with mild
essel.
Figure 2 Postoperative gross examination of mass. On
macroscopical examination, the lesion was gray-red solitary nodular
mass without gross necrosis, haemorrhage and calcification. There was
no fibrous capsule round the mass.
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CD117 (Figure 4). The field of MEC and type B2 thym-
oma was distinct in the mass, there was no gradual
transition of these two parts observed in mass although
they were close to each other in some areas. Based on
above findings, a final histological diagnosis of primary
combined type B2 thymoma/MEC of thymus was
made, and the final staging of this tumor was stage II
(Masaoka staging system).
The postoperative phase was uneventful and the dysarth-
ria resolved. After diagnosis, the patient was started on
pyridostigmine with a remarkable improvement in weak-
ness, diplopia and ptosis. Chemotherapy with regiments of
cisplatin and mitomycin, and radiotherapy of the main
tumor bed were performed on the patient. Since there was
a possibility of tumor metastasis to another anatomical lo-
cation, the patient was referred to a whole body positron
emission tomography (PET)/CT study to search for the po-
tentially secondary tumor, but no abnormality was found.
The patient was on regular follow-up for 12 months after
discharging from hospital. He had remained asymptomatic,
and there was no evidence of tumor recurrence during the
period of postoperative follow-up.
Discussion
Combined thymic epithelial tumors are rare and charac-
terized by at least two distinct areas each corresponding
to one of the histological thymoma and thymic carcin-
oma types [16]. The etiology of these tumors remains
enigmatic. Some genetic studies suggested that com-
bined thymic epithelial tumors could arise by dedifferen-
tiation of thymoma/thymic carcinoma or by biphasic
differentiation of a multipotential thymic epithelial pre-
cursor. However, the concept of tumor collision awaits
genetic evidence [3]. Clinically, almost all reported casesof combined thymic tumors were observed in the anter-
ior mediastinum, and there were no differences in the
clinical manifestations of combined tumors as compared
to the individual component. Myasthenia gravis (MG) is
by far the most common paraneoplastic manifestation.
Histologically, over 80% of combined tumors have type
B2 and B3 component. But rare cases of combined type
AB thymoma or spindle cell (type A) thymoma with
thymic carcinoma has also been described [18,19]. The
carcinoma component in the most cases is squamous
cell carcinoma. Lymphoepithelioma-like, sarcomatoid/
anaplastic or undifferentiated carcinomas are uncom-
mon. In the present case, the typical MEC and type B2
thymoma could be identified in different areas of the
same tumor. The patient showed a mass in anterior
mediastinum with typical manifestations of myasthenia
gravis. These findings were consistent with the diagnos-
tic criteria of combined type B2 thymoma/MEC of thy-
mus. To our best knowledge, so far there is no report to
describe a coexistence of thymoma and primary MEC
within thymic tumor. Our case is the first case of com-
bined thymic epithelial tumor with MEC component.
MEC is a relatively common neoplasm of the salivary
glands, which rarely arises in other sites, including esopha-
gus, anal canal, skin of the breast, lachrymal sac, thyroid
gland, or uterine cervix [20-23]. Primary thymic MEC is
rare. It was first described by Snover DC and his col-
leagues in 1982 [3]. Since then, no more than 30 cases
have been reported in the English literature [4-15]. Despite
its distinct histological morphology, the pathogenesis of
MEC of thymus is still unknown. It has been suggested
that thymic MECs might arise from thymic epithelium be-
cause, in some cases, a transition between tumor cells and
benign cyst-lining epithelium and the finding of residual
non-neoplastic thymic parenchyma within the walls of the
cysts has been reported in some cases [7]. However, pluri-
potent epithelial stem cells of endodermal origin have
been also postulated in the pathogenesis of MEC of the
thymus by some authors [3]. A strong association between
MEC and t (11; 19) (q21; p13) has been observed in non-
thymic anatomical sites [24,25]. Recent study has demon-
strated that MAML2 rearrangement, a member of the
Master Mind Like gene family on chromosome 11q21, is
harbored specifically in thymic MEC similar to MEC in
other anatomical sites, suggesting thymic MEC is not only
histologically but also biologically related to non-thymic
cases of MEC [15]. It is necessary for the further study to
clarify if MAML2 rearrangement presents in the rare
MEC component of combined thymic epithelial tumors.
The establishment of a preoperative diagnosis of thymic
MEC is difficult because of the rarity of this tumor and the
fact that there are no specific landmarks in the radiologic
examinations. Therefore, percutaneous biopsy is needed
for this tumor to obtain a definite diagnosis preoperatively
Wu et al. Diagnostic Pathology 2014, 9:8 Page 4 of 7
http://www.diagnosticpathology.org/content/9/1/8[14]. In the current study, a CT guided fine needle biopsy
of the anterior mediastinal mass was performed. However,
only type B2 thymoma was observed in the biopsy because
it was difficult for pathologists to provide a precise diagno-
sis from a few very small tumor tissues in rare combined
thymic tumor. Under these extremely rare conditions, suf-
ficient tissue from different parts of the lesion and thor-
oughly histological inspection are necessary for accurate
diagnosis. Even if a diagnosis of thymic MEC is confirmed
by biopsy examination, the possibility of a metastasis from
primary MEC occurring in common sites should also be
excluded. Thoroughly body examination and a whole body
PET/CT study are useful to find the potentially primary
tumor. In our case, no primary tumor of MEC was found
by whole body PET/CT study.
Histologically, MEC in thymus and other anatomical
sites are characterized by squamoid (epidermoid), mucin-
producing and cells of intermediate type with varyingFigure 3 Postoperative photomicrographs of lesion in MEC compone
mucin-producing areas (left side of the figure) and lymphocyte-rich areas (righ
component, respectively. (b) High magnification showed the mucin-producin
Invasive nests of well-differentiated epidermoid cells, mucin-producing and int
tissue were observed in the tumor. (d) The epidermoid cells were observed to b
(e) MEC component was negative for CD5. (f) The Alcian blue-positive material
the nest of epidermoid cells. (a, H & E staining with original magnification of 20
immunohistochemical staining with original magnification of 400 ×; f, Alcian bluproportion and architectural configuration in and between
tumors [26]. The presence of mucin-producing cells in the
tumor is the key diagnostic clue for MEC. However, the
presence of mucinous differentiation in a thymic neo-
plasm is not uncommon. Mucinous epithelium can be oc-
casionally noted in the normal human thymus and in
thymomas [27]. It more frequently occurs in the thymus of
dogs and other animals, and reflects the potential of the
thymic epithelium to differentiate along multiple cell lines
[4]. Thus, thymic MEC might be confused by thymomas
with mucinous differentiation. However, the latter lacks the
intermediate type cells and invasive nests of epidermoid
cells with desmoplastic stroma. Thymic MEC is sometimes
misdiagnosed as squamous cell carcinoma of thymus as the
tumor presents predominantly nests of invasive epidermoid
cells with inconspicuous mucin-producing cells compo-
nent. Since the MEC is rare in thymus, these morphological
features might be erroneously interpreted squamous cellnt. (a) The tumor was composed of nests of epidermoid cells with
t side of figure). They represented the MEC component and thymoma
g cells were surrounded by epidermoid cells in MEC component. (c)
ermediate cells were observed in MEC areas. Bands of fibrous connective
e positive for CK5/6, but the mucin-producing cells were CK5/6-negative.
was seen in lumen of gland structure and the mucin-producing cells within
0 ×; b-c, H & E staining with original magnification of 400 ×; d-e,
e staining with original magnification × 400).
Figure 4 Postoperative photomicrographs of lesion in thymoma component. (a) The neoplastic cells were large and polygonal with large
nuclei and prominent central nucleoli in the lymphocyte-rich background. (b) Some small epidermoid foci resembling abortive Hassall’s
corpuscles could be observed among the neoplastic epithelial cells, but no mucin-producing cells were found in these epidermoid foci. In these
areas, the neoplastic cells were diffusely positive for CK19 (c), but negative for CD5 (d). (a-b, H & E staining with original magnification of 400 ×;
c-d, immunohistochemical staining with original magnification of 400 ×).
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tion. However, mucin-producing cell is absent in the squa-
mous cell carcinoma, which can be demonstrated in
majority of tumor by Alcian blue and diastase-PAS staining.
Sufficient tissue from different parts of the tumor and thor-
ough inspection to find the mucin-producing cells will fa-
cilitate the precise diagnosis of MEC. More importantly,
thymic squamous cell carcinomas are immunoreactive to
CD5, which are quite useful to distinguish it from thymic
MEC and other non-thymic origin squamous cell carcin-
oma. Like most of reported cases, the MEC component of
our case also presented the immunohistochemical negativ-
ity to CD5, supporting the diagnosis of MEC rather than
squamous cell carcinoma. However, only one previously
reported case of thymic MEC showed tumor cells were
positive to CD5 [14]. It is not clear whether this immuno-
reaction represents a specifically diagnostic marker or an
aberrant expression. More cases of primary thymic MEC
should be needed to confirm this immunophenotype. In
addition, multilocular cystic structures may be frequently
observed in thymic MEC, the differential diagnosis of cys-
tic masses in anterior mediastinum, even rare ectopic pan-
creatic pseudocyst, should be included [28].
Available data on combined thymic epithelial tumors
suggest that the most aggressive component of tumor
determines the clinical outcome. As to thymic MEC,
high-grade tumors have been demonstrated more inva-
sive and shown stronger tendency for metastasis com-
pared with low-grade tumors [18,19]. Among the casesreported with known pathological grades and clinical
courses, mortality was limited to the high-grade type
of MEC. In the present case, the MEC component was
low-grade type according to the WHO grading criteria
because the tumor lacked the histological features of
neural invasion, cystic formation, necrosis and active
mitotic figures [17]. Type B2 thymoma is a tumor of
moderate malignancy with invasiveness and recur-
rence, even after complete resection. Recent study has
demonstrated that the overexpression of c-Jun, p73
and Caspase-9 in thymic epithelial tumors is closely re-
lated with the pathogenesis and biological behavior of
the neoplasms [29]. To date, there are no established
therapeutic regimens for thymic MEC because of the
rarity of this tumor. The published experience with
chemotherapy for MEC has been limited, but the tu-
mors have been suggested to be chemosensitive [30].
Most regimens for thymic carcinoma are similar to
those for thymoma and include cisplatin [31,32]. Sig-
nificant beneficial effect of cisplatin-based combin-
ation chemotherapy for inoperable thymic carcinomas
has been suggested in several studies [31-33]. In the
present case, there was no evidence of tumor recur-
rence during the period of postoperative follow-up. We
presume that low-grade of tumor and chemotherapy
with cisplatin regimen might be associated with favor-
able results. Of course, a longer follow-up period and
laboratory examinations are needed to inspect the long
term prognosis of our patient.
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In summary, we herein first reported a rare case of com-
bined thymic MEC/thymoma in an anterior mediastinal
mass. The mass contained two separated components and
displayed typically histological features of low-grade MEC
and type B2 thymoma, respectively. The precise mechan-
ism of coexistence of MEC and thymoma in the same
nodule remains unknown, and longer period of follow-up
and more case investigation are necessary to better clarify
the biological characteristics and clinical outcomes of this
unusual tumor. Although this tumor is rare, the diagnosis
of a thymic MEC should be taken into consideration when
a combined epithelial tumor is occasionally encountered
in thymus.Consent
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